What’s Up with U.S. Merger Remedies? A Podcast Episode Featuring Jeny Maier
February 26, 2024, 3:14 PM
By: Axinn Insights
The US antitrust agencies’ approach to merger remedies has undergone a significant change under the Biden administration. Remedies are increasingly disfavored.
Axinn's Managing Partner Jeny Maier joins Dan Ducore, former Assistant Director of the Federal Trade Commission’s Bureau of Competition Compliance Division, and co-host Barry Nigro on Our Curious Amalgam to discuss the growing skepticism towards merger remedies by the US antitrust authorities.
Listen to this episode to learn more about whether merger remedies remain a viable option in the US and, if so, how parties should approach them given the government’s current hostility toward remedies.
To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
The Empty Chair in Antitrust Conspiracy Cases
Webinar
Antitrust
USC Gould/Analysis Group Global Competition Law Thought Leadership Conference
Speaking Engagement
Antitrust
17th ACI Summit on Biosimilars & Innovator Biologics
Speaking Engagement
Intellectual Property
GCR Live: Europe 2026
Speaking Engagement
Antitrust
20th Annual IBA Competition Mid-Year Conference
Speaking Engagement
Antitrust
Axinn Partners Named to Lawdragon 500 Leading Global Litigators 2026
News
Litigation & Trials
Turning Up the Heat: Federal Circuit Sets the Temperature for pH Measurements in Precedential Opinion
Axinn Viewpoints
Intellectual Property
Axinn Represents Tecomet in Closing of Merger with Orchid Orthopedic
Deals & Cases
Antitrust
Recent Benchmarking Suits Highlight DOJ Enforcement Risks
Byline Articles
Antitrust
“Old Crime, New Code” – DOJ Outlines its Views on When Software and AI Can Facilitate Collusion
Axinn Viewpoints
Antitrust